- Details
- Urologist Neal Shore joins Alicia Morgans in a conversation on the multidisciplinary approach and successful incorporation of radium-223 dichloride (radium-223) into the treatment algorithm for men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. Drs. Shore and Morgans talk through the challenges care teams face when planning the administration of radiu...
|
- Details
- In this discussion, Nicholas James and Alicia Morgans discuss the relationship between alkaline phosphatase decline and overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases treated with radium-223 (Ra-223) in the global real-world REASSURE study. REASSURE is evaluating the long-term safety of Radium 223 in routine clinical practice in...
|
- Details
- Zachary Klaassen discusses The Journal of Urology publication entitled "Association Between Treatment for Localized Prostate Cancer and Mental Health." This study compares patient-reported mental health outcomes for men undergoing treatment for localized prostate cancer over 5 years using the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study. Biographies: Zachary Klaassen,...
|
- Details
- In this UroToday Journal Club, Zach Klaassen highlights a European Urology Oncology publication entitled Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-Based Biopsy in Men on Active Surveillance for Prostate Cancer -- Data from the Multi-International Multicenter Prospective PRIAS Study . In general, the use of MRI prior to initial biopsy is now relatively widely manda...
|
- Details
- In this UroToday Journal Club, Zach Klaassen highlights a European Urology publication entitled High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium . Radiotherapy is a standard-of-care treatment approach for patients with localized prostate cancer, and t...
|
- Details
- Ashish Kamat, Joan Palou, and Fred Witjes discuss optimal management of high-grade T1 bladder cancer. This rapid-fire debate is formatted as each speaker has a position to defend and they will each offer their view for why that treatment is optimal. Biographies: J. Alfred Witjes, MD, Ph.D., Full professor at the Radboud Institute for Molecular Life Sciences, Faculty of Medical Sciences, Chair of O...
|
- Details
- Ashish Kamat and Kari Tikkinen discuss guidelines on thromboprophylaxis in urological surgery. Dr. Tikkinen gives a step-by-step guide through deciding to use thromboprophylaxis, starting with demonstrating that prophylaxis works and then discussing what constitutes a need for thromboprophylaxis for the patient. They also discuss cases where the guidelines may falter and how to troubleshoot in tho...
|
- Details
- Chadi Nabhan joins Charles Ryan to discuss The Caris Precision Oncology Alliance™ (POA), which focuses on precision oncology to optimize clinical care and outcomes of patients with cancer. The Precision Oncology Alliance gathers real-world data from patients that undergo molecular tumor profiling across the spectrum of solid malignancies and feeds the data into a large database that can be accesse...
|
- Details
- Niyati Lobo joins Ashish Kamat in a conversation about the updated European Association of Urology (EAU) prognostic risk groups and whether or not the updates appropriately consider patients treated with BCG. Dr. Lobo discusses the applicability of the updated groups in a contemporary cohort of non-muscle-invasive bladder cancer (NMIBC) patients at MD Anderson treated with bacillus Calmette-Guérin...
|
- Details
- Thomas Powles discusses the results of the CALYPSO trial with Pedro Barata. Dr. Powles provides an overview of the trial design of this international, multicentre, open-label phase Ib/IIa study of durvalumab alone, savolitinib alone, and durvalumab in combination with savolitinib or tremelimumab in patients with metastatic renal cell cancer. He then discusses the trial results, plus his thoughts o...
|
